Last update 01 Jul 2024
Sym-021
Last update 01 Jul 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms ANTI-PD-1, S-95016, SYM 021 |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Related
8
Clinical Trials associated with Sym-021Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer(AuspiCiOus-dMMR): a proof-of-principle study
Start Date03 Apr 2024 |
Sponsor / Collaborator- |
Cohort study of SABR combined with anti-PD-1 and targeted therapy versus anti-PD-1 and targeted therapy for recurrent or metastatic renal cell carcinoma patients
Start Date01 Apr 2024 |
Sponsor / Collaborator |
A Phase 1a/1b, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Anti-neoplastic Activity of S095029 (Anti-NKG2A) as Monotherapy and in Combination With Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triplet Combinations of S095029 and Sym021 and an Anti-HER2 mAb or Anti-EGFR mAbs (Futuximab/Modotuximab) in Patients With Metastatic Gastric or Colorectal Cancers
The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations.
Start Date15 Oct 2021 |
Sponsor / Collaborator |
100 Clinical Results associated with Sym-021
Login to view more data
100 Translational Medicine associated with Sym-021
Login to view more data
100 Patents (Medical) associated with Sym-021
Login to view more data
4
Literatures (Medical) associated with Sym-02101 Dec 2020·Journal of hematology & oncologyQ1 · MEDICINE
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer
Q1 · MEDICINE
ArticleOA
Author: Dong, Xiaorong ; Wu, Gang ; Chen, Yaobing ; Zhou, Xiaoshu ; Xu, Shuangbing ; Zhang, Tao ; Liu, Li ; Meng, Rui ; Zhang, Sheng ; Hong, Jiaxin ; Zhang, Ruiguang ; Wang, Jian ; Tang, Jing ; Zong, Yan ; Lin, Zhenyu ; Yang, Kunyu ; Xu, Yingzhuo
Abstract:
Background:
The cyclin-dependent kinase 7 (CDK7) subunit of TFIIH regulates RNA polymerase-II-based transcription and promotes tumor progression. However, the mechanisms involved in CDK7-mediated immune evasion are unclear in non-small cell lung cancer (NSCLC).
Methods:
RNA silencing and pharmacologic inhibitors were used to evaluate the functions of CDK7/p38α/MYC/PD-L1 axis in cancer cell proliferation and antiPD-1 therapy resistance. Flow cytometry was performed to detect the status of the immune microenvironment after CDK7 inhibition and antiPD-1 therapy in vivo. CD8 depletion antibodies were used to assess the role of CD8+ T cells in combined CDK7 and PD-1 blockade. The associations among CDK7, p38α, MYC, PD-L1, infiltrating T cells, and survival outcomes were validated in two tissue microarrays and public transcriptomic data of NSCLC.
Results:
High CDK7 mRNA and protein levels were identified to be associated with poor prognosis in NSCLC. CDK7 silencing and CDK7 inhibitor THZ1 elicited apoptosis and suppressed tumor growth. Moreover, CDK7 ablation specifically suppressed p38α/MYC-associated genes, and THZ1 inhibited MYC transcriptional activity through downregulating p38α. CDK7 inhibition sensitized NSCLC to p38α inhibitor. Further, THZ1 suppressed PD-L1 expression by inhibiting MYC activity. THZ1 boosted antitumor immunity by recruiting infiltrating CD8+ T cells and synergized with antiPD-1 therapy. The CDK7/MYC/PD-L1 signature and infiltrating T cell status collectively stratified NSCLC patients into different risk groups.
Conclusion:
These data suggest that the combined CDK7 inhibitor THZ1 and antiPD-1 therapy can be an effective treatment in NSCLC.
19 May 2019·mAbsQ2 · MEDICINE
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform
Q2 · MEDICINE
Article
Author: Bouquin, Thomas ; Uhlenbrock, Franziska ; Pedersen, Mikkel W ; Lindsted, Trine ; Kragh, Michael ; Horak, Ivan D ; Gad, Monika ; Fröhlich, Camilla ; Dietrich, Nikolaj ; Galler, Gunther R ; Gjetting, Torben ; Grandal, Michael M ; Melander, Maria C ; Koefoed, Klaus ; Bhatia, Vikram K ; Strandh, Magnus ; Lantto, Johan
Discovery of therapeutic antibodies is a field of intense development, where immunization of rodents remains a major source of antibody candidates. However, high orthologue protein sequence homology between human and rodent species disfavors generation of antibodies against functionally conserved binding epitopes. Chickens are phylogenetically distant from mammals. Since chickens generate antibodies from a restricted set of germline genes, the possibility of adapting the Symplex antibody discovery platform to chicken immunoglobulin genes and combining it with high-throughput humanization of antibody frameworks by "mass complementarity-determining region grafting" was explored. Hence, wild type chickens were immunized with an immune checkpoint inhibitor programmed cell death 1 (PD1) antigen, and a repertoire of 144 antibodies was generated. The PD1 antibody repertoire was successfully humanized, and we found that most humanized antibodies retained affinity largely similar to that of the parental chicken antibodies. The lead antibody Sym021 blocked PD-L1 and PD-L2 ligand binding, resulting in elevated T-cell cytokine production in vitro. Detailed epitope mapping showed that the epitope recognized by Sym021 was unique compared to the clinically approved PD1 antibodies pembrolizumab and nivolumab. Moreover, Sym021 bound human PD1 with a stronger affinity (30 pM) compared to nivolumab and pembrolizumab, while also cross-reacting with cynomolgus and mouse PD1. This enabled direct testing of Sym021 in the syngeneic mouse in vivo cancer models and evaluation of preclinical toxicology in cynomolgus monkeys. Preclinical in vivo evaluation in various murine and human tumor models demonstrated a pronounced anti-tumor effect of Sym021, supporting its current evaluation in a Phase 1 clinical trial. Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CD, cluster of differentiation; CDC, complement-dependent cytotoxicity; CDR, complementarity determining region; DC, dendritic cell; ELISA, enzyme-linked immunosorbent assay; FACS, fluorescence activated cell sorting; FR, framework region; GM-CSF, granulocyte-macrophage colony-stimulating factor; HRP, horseradish peroxidase; IgG, immunoglobulin G; IL, interleukin; IFN, interferon; mAb, monoclonal antibody; MLR, mixed lymphocyte reaction; NK, natural killer; PBMC, peripheral blood mono-nuclear cell; PD1, programmed cell death 1; PDL1, programmed cell death ligand 1; RT-PCR, reverse transcription polymerase chain reaction; SEB, Staphylococcus Enterotoxin B; SPR, surface Plasmon Resonance; VL, variable part of light chain; VH, variable part of heavy chain.
01 Jan 2019·TheranosticsQ1 · MEDICINE
CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models
Q1 · MEDICINE
ArticleOA
Author: Kristensen, Lotte K ; Kragh, Michael ; Melander, Maria C ; Galler, Gunther R ; Lantto, Johan ; Kjaer, Andreas ; Nielsen, Carsten H ; Horak, Ivan D ; Fröhlich, Camilla ; Christensen, Camilla ; Poulsen, Thomas T
Predicting the outcome of immunotherapy is essential for efficient treatment. The recent clinical success of immunotherapy is increasingly changing the paradigm of cancer treatment. Accordingly, the development of immune-based agents is accelerating and the number of agents in the global immuno-oncology pipeline has grown 60-70% over the past year. However, despite remarkable clinical efficacy in some patients, only few achieve a lasting clinical response. Treatment failure can be attributed to poorly immunogenic tumors that do not attract tumor infiltrating lymphocytes (TILs). Therefore, we developed positron emission tomography (PET) radiotracers for non-invasive detection of CD4+ and CD8a+ TILs in syngeneic mouse tumor models for preclinical studies. Methods: Seven syngeneic mouse tumor models (B16F10, P815, CT26, MC38, Renca, 4T1, Sa1N) were quantified for CD4+ and CD8a+ TILs using flow cytometry and immunohistochemistry (IHC), as well as for tumor growth response to Sym021, a humanized PD-1 antibody cross-reactive with mouse PD-1. Radiotracers were generated from F(ab)'2 fragments of rat-anti-mouse CD4 and CD8a antibodies conjugated to the p-SCN-Bn-Desferrioxamine (SCN-Bn-DFO) chelator and radiolabeled with Zirconium-89 (89Zr-DFO-CD4/89Zr-DFO-CD8a). Tracers were optimized for in vivo PET/CT imaging in CT26 tumor-bearing mice and specificity was evaluated by depletion studies and isotype control imaging. 89Zr-DFO-CD4 and 89Zr-DFO-CD8a PET/CT imaging was conducted in the panel of syngeneic mouse models prior to immunotherapy with Sym021. Results: Syngeneic tumor models were characterized as "hot" or "cold" according to number of TILs determined by flow cytometry and IHC. 89Zr-DFO-CD4 and 89Zr-DFO-CD8a were successfully generated with a radiochemical purity >99% and immunoreactivity >85%. The optimal imaging time-point was 24 hours post-injection of ~1 MBq tracer with 30 µg non-labeled co-dose. Reduced tumor and spleen uptake of 89Zr-DFO-CD8a was observed in CD8a+ depleted mice and the uptake was comparable with that of isotype control (89Zr-DFO-IgG2b) confirming specificity. PET imaging in syngeneic tumor models revealed a varying maximum tumor-to-heart ratio of 89Zr-DFO-CD4 and 89Zr-DFO-CD8a across tumor types and in-between subjects that correlated with individual response to Sym021 at day 10 relative to start of therapy (p=0.0002 and p=0.0354, respectively). The maximum 89Zr-DFO-CD4 tumor-to-heart ratio could be used to stratify mice according to Sym021 therapy response and overall survival was improved in mice with a 89Zr-DFO-CD4 ratio >9 (p=0.0018). Conclusion: We developed 89Zr-DFO-CD4 and 89Zr-DFO-CD8a PET radiotracers for specific detection and whole-body assessment of CD4+ and CD8a+ status. These radiotracers can be used to phenotype preclinical syngeneic mouse tumor models and to predict response to an immune checkpoint inhibitor. We foresee development of such non-invasive in vivo biomarkers for prediction and evaluation of clinical efficacy of immunotherapeutic agents, such as Sym021.
1
News (Medical) associated with Sym-02111 Oct 2022
The prevalence of esophageal cancer has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing prevalence of cancer and the increase in research & development. The Companies developing the potential therapies in the last stage of development include Celgene,Jiangsu HengRui Medicine Co., Seagen, and several others.
LAS VEGAS, Oct. 11, 2022 /PRNewswire/ -- DelveInsight's
'
Esophageal Cancer Pipeline Insight – 2022
' report provides comprehensive global coverage of available, marketed, and pipeline esophageal cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the esophageal cancer pipeline domain.
Key Takeaways from the Esophageal Cancer Pipeline Report
DelveInsight's esophageal cancer pipeline report depicts a robust space with
80+ active players working to develop
90+ pipeline therapies for esophageal cancer treatment.
Leading esophageal cancer companies such as
Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others are evaluating new drugs for esophageal cancer treatment.
Key esophageal cancer pipeline therapies in various stages of development include
Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, AP 203, QEQ278, JAB-3312, DKN-01, AN0025, HR 070803,Oraxol, Sunitinib malate, Tiragolumab, iNeo Vac P01, Amivantamab, CA-4948, M1231, APX005M, DC-CIK, Margetuximab, Temozolomide, and others.
In
September 2022,
Daiichi Sankyo and
Sarah Cannon Research Institute (SCRI) announced that extended follow-up data from a phase I/II trial of
DS-7300, continued to show promising durable tumor response in patients with several types of heavily pretreated cancers including lung, prostate or esophageal cancer.A response rate of 32% (95% CI: 24-41) was observed with 38 responses (33 confirmed; 28%; 95% CI: 20-37) in 118 patients with various solid tumors including small cell lung cancer (SCLC), squamous non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC) or endometrial cancer receiving doses of DS-7300 ranging from 4.8 mg/kg to 16.0 mg/kg.
In
September 2022,
Integral Molecular, has
licensed a panel of monoclonal antibodies (MAbs) to
CARTEXELL, enabling CARTEXELL to develop CAR-T cell therapies using Integral Molecular's Claudin 18.2 (CLDN18.2) MAbs. Under the terms of the agreement, Integral Molecular will provide an exclusive worldwide license to CARTEXELL to use the panel of high-affinity, high-specificity, and fully humanized CLND18.2 MAbs for the development of CAR-T cell therapies against solid tumors including gastric, lung, pancreatic and esophageal cancers. CARTEXELL will be solely responsible for all research, development, and commercial activities.
In
August 2022,
BeiGene announced that the
Center for Drug Evaluation (CDE) of the China
National Medical Products Administration (NMPA) has accepted a
supplemental biologics license application (sBLA) for
tislelizumab in combination with chemotherapy as first-line treatment in patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
In
May 2022,
Shanghai Junshi Biosciences Co., Ltd, announced that the
China National Medical Products Administration (NMPA) has approved the
supplemental new drug application (sNDA) for
toripalimab in combination with paclitaxel and cisplatin in the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC). The sNDA was accepted by the NMPA in July 2021. This is the fifth indication approved for toripalimab in China and will benefit Chinese patients with advanced ESCC.
In
May 2022,
Bristol Myers Squibb, announced that the U.S.
Food and Drug Administration (FDA) has
approved both
Opdivo (nivolumab) (injection for intravenous use) in combination with fluoropyrimidine- and platinum-containing chemotherapy and
Opdivo plus Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status. The approvals are based on the Phase III CheckMate -648 trial, which evaluated Opdivo in combination with chemotherapy (n=321) and Opdivo plus Yervoy (n=325) each compared to chemotherapy alone (n=324), and was the largest Phase III trial of immunotherapy in first-line ESCC.
In
January 2022,
Lyell Immunopharma, Inc., announced that the U.S.
Food and Drug Administration (FDA) has cleared an
Investigational New Drug (IND) application to initiate a Phase I clinical trial for
LYL132, an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1) that the company is developing in collaboration with GSK.
Request a sample and discover the recent advances in esophageal cancer treatment @
Esophageal Cancer Pipeline Report
The esophageal cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage esophageal cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the esophageal cancer pipeline landscape.
Esophageal Cancer Overview
Esophageal cancer grows in the esophagus, the tube that connects the throat to the stomach. Tumors develop in the mucosa, the inner lining of the esophagus. Esophageal cancer is classified into two types, each with its own set of risk factors: Adenocarcinoma -Adenocarcinomas are cancers that begin in gland cells at the bottom of the esophagus. This is the most common type of esophageal cancer. It usually happens near the stomach. The exact esophageal cancer causes are not known.
Most esophageal cancer symptoms do not appear until cancer has progressed to an advanced stage, when it may be challenging to treat. Other, more common conditions can cause esophageal cancer symptoms. The most common esophageal cancer symptom is difficulty swallowing, particularly a sensation of food stuck in the chest.
There are several tests used for esophageal cancer diagnosis. The most common include endoscopy with biopsy and endoscopic ultrasonography.
Find out more about esophageal cancer drugs in development @
New Treatment for Esophageal Cancer
A snapshot of the Esophageal Cancer Pipeline Drugs mentioned in the report:
Learn more about the emerging esophageal cancer pipeline therapies @
Esophageal Cancer Clinical Trials
Esophageal Cancer Therapeutics Assessment
The
esophageal cancer pipeline report proffers an integral view of esophageal cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Esophageal Cancer Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment
By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
Therapeutics Assessment
By Molecule Type: Oligonucleotide, Peptide, Small molecule
Therapeutics Assessment
By Mechanism of Action: Prostaglandin E EP4 receptor antagonists, ERBB 2 receptor antagonists, Phosphorylation inhibitors, Antibody-dependent cell cytotoxicity, Apoptosis stimulants, CD40 antigen stimulants, Immunostimulants, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Epidermal growth factor receptor antagonists.
Key Esophageal Cancer Companies: Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL and others
Key Esophageal Cancer Pipeline Therapies: Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, AP 203, QEQ278, JAB-3312, DKN-01, AN0025, HR 070803,Oraxol, Sunitinib malate, Tiragolumab, iNeo Vac P01, Amivantamab, CA-4948, M1231, APX005M, DC-CIK, Margetuximab, Temozolomide and others.
Dive deep into rich insights for esophageal cancer drugs, visit @
Chemo Drugs for Esophageal Cancer Treatment
Table of Contents
For further information on the esophageal cancer pipeline therapeutics, reach out @
New Drug for Esophageal Cancer Treatment
Related Reports
Esophageal Cancer Market
Esophageal Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key esophageal cancer companies including
Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, among others.
Esophageal Cancer Epidemiology Forecast
Esophageal Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted esophageal cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Esophageal Squamous Cell Carcinoma Pipeline
Esophageal Squamous Cell Carcinoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key esophageal squamous cell carcinoma companies, including
BeiGene, AstraZeneca, Ipsen, Shire, Sanofi, Seagen, among others.
Esophageal Squamous Carcinoma Market
Esophageal Squamous Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key esophageal squamous carcinoma companies, including
BeiGene, AstraZeneca, Ipsen, Shire, Sanofi, Seagen, among others.
Esophageal Squamous Cell Carcinoma Epidemiology
Esophageal Squamous Cell Carcinoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted esophageal squamous cell carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Goitre Market
|
Thymus Cancer Market
|
US Healthcare Outlook Report
|
Venous Stenosis Market
|
Negative Pressure Wound Therapy Systems Market
|
Global Kinase Inhibitor in Autoimmune Diseases Market
|
Metrorrhagia Market
|
Dysfunctional Uterine Bleeding Market
|
Hypereosinophilic Syndrome Market
|
Age-related Vision Dysfunction Market
|
Dental Lasers Market
|
CRISPR Therapies Pipeline Insight
|
Cell And Gene Therapy For Multiple Myeloma Market
|
Drug Hypersensitivity Market
|
Dysthymia Market
|
Persistent Depressive Disorder Market
|
Cancer Vaccines Market
|
Weight Loss/Weight Management (Obesity) Market |
Food Allergy Market |
Obsessive-Compulsive Disorder Market |
Tumor Ablation Market |
Physiotherapy Equipment Market |
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market |
Anti-hypertension Market |
Radiofrequency Ablation Devices Market |
Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |
Gastro Intestinal Bleeding Market |
Trastuzumab Biosimilars Insight |
Varicose Veins Market |
Germ Cell Tumor Market |
Intracardiac Echocardiography Devices Market |
India Healthcare Report |
Crows Feet Market |
Seborrhoeic Dermatitis Market |
Injectable Drug Delivery Devices Market |
Structural Heart Devices Market |
Substance (Drug) Abuse Market |
Insulin Glargine Biosimilar Insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
Gene TherapyAntibodyBiosimilarOligonucleotideCell Therapy
100 Deals associated with Sym-021
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Relapsed Solid Neoplasm | Phase 1 | US | 12 Oct 2020 | |
| Relapsed Solid Neoplasm | Phase 1 | CA | 12 Oct 2020 | |
| Relapsed Solid Neoplasm | Phase 1 | FR | 12 Oct 2020 | |
| Relapsed Solid Neoplasm | Phase 1 | ES | 12 Oct 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | US | 20 Nov 2017 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CA | 20 Nov 2017 | |
| Lymphoma | Phase 1 | US | 20 Nov 2017 | |
| Lymphoma | Phase 1 | CA | 20 Nov 2017 | |
| Neoplasm Metastasis | Phase 1 | US | 20 Nov 2017 | |
| Neoplasm Metastasis | Phase 1 | CA | 20 Nov 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
Not Applicable | Recurrent Squamous Cell Carcinoma of the Head and Neck PD-L1 positive (CPS≥1) | 89 | dagbirpdnt(cccipgorlv) = 10% bonoptpcno (fhifnprjiu ) View more | Positive | 24 May 2024 | ||
Not Applicable | 86 | nvnaynmdlv(lkshlaeuki) = qtxxhqzsux nbjeryopge (wevlwcgnrn ) View more | Positive | 31 May 2023 | |||
Not Applicable | Advanced Lung Non-Small Cell Carcinoma EGFR mutation positive | 67 | arbttfbzfn(pmamqdrlol) = kejfhnirka czhxdbpilc (hahnxyvflj ) View more | - | 15 Mar 2021 | ||
Phase 1 | - | fyedtylcfu(njlzumzsin) = Sym021, Sym022 and Sym023 alone and Sym021 in combination with either Sym022 or Sym023 were well tolerated with AE profiles typical of immune checkpoint inhibitors ufwvmoejel (nvafmilcmi ) | - | 20 Sep 2020 | |||
Not Applicable | 51 | (HLA-A2 supertype) | kmiewbrinb(gjrpxliwke) = dvifbsbbdu nwmbsgjxfy (bgkwbyjapp ) | - | 01 Apr 2020 | ||
(Patients without HLA-A2 supertype) | kmiewbrinb(gjrpxliwke) = uzjrodxkdl nwmbsgjxfy (bgkwbyjapp ) | ||||||
Not Applicable | Melanoma Last line | 200 | fbxywjjmoe(ktkwkimkec) = dxuugssdha xmlgkrfffg (tdhcwimolc ) View more | - | 30 Sep 2019 | ||
Not Applicable | - | aPD1 | ggzgpraxxc(mcpbqbmdve) = gqyxnwdpsi lsgnzgxolj (gdhwsonkpg ) View more | - | 30 May 2017 | ||
aPD1 + IPI | vqvokzqauz(uqalirihaa) = lnzegtplge qiybdhhysc (vezbfhivsq ) View more | ||||||
Not Applicable | 64 | aPD1 + aCTLA4 | hkcfhholxk(yqsxswtfax) = One death from irAEs occurred related to Toxic Epidermal Necrolysis (TEN) jvxedzzzjr (glywgdmotr ) View more | Positive | 30 May 2017 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free